Literature DB >> 17160672

Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia.

F Porcellati1, S Pampanelli, P Rossetti, N Busciantella Ricci, S Marzotti, P Lucidi, F Santeusanio, G B Bolli, C G Fanelli.   

Abstract

AIMS/HYPOTHESIS: The aim of our study was to establish whether the well-known defective or absent secretion of glucagon in type 1 diabetes in response to hypoglycaemia is selective or includes lack of responses to other stimuli, such as amino acids.
MATERIALS AND METHODS: Responses of glucagon to hypoglycaemia were measured in eight patients with type 1 diabetes and six non-diabetic subjects during hyperinsulinaemic (insulin infusion 0.5 mU kg(-1) min(-1)) and eu-, hypo- and hyperglycaemic clamp studies (sequential steps of plasma glucose 5.0, 2.9, 5.0, 10 mmol/l). Subjects were studied on three randomised occasions with infusion of low- or high-dose alanine, or saline.
RESULTS: With saline, glucagon increased in hypoglycaemia in non-diabetic subjects but not in diabetic subjects. Glucagon increased further with low-dose (181 +/- 16 ng l(-1) min(-1)) and high-dose alanine (238 +/- 20 ng l(-1) min(-1)) in non-diabetic subjects, but only with high-dose alanine in diabetic subjects (area under curve 112 +/- 5 ng l(-1) min(-1)). The alanine-induced glucagon increase in diabetic subjects paralleled the spontaneous glucagon response to hypoglycaemia in non-diabetic subjects not receiving alanine. The greater responses of glucagon to hypoglycaemia with alanine infusion were offset by recovery of eu- or hyperglycaemia. CONCLUSIONS/
INTERPRETATION: In type 1 diabetes, the usually deficient responses of glucagon to hypoglycaemia may improve after increasing the concentration of plasma amino acids. Amino acid-enhanced secretion of glucagon in response to hypoglycaemia remains under physiological control since it is regulated primarily by the ambient plasma glucose concentration. These findings might be relevant to improving counter-regulatory defences against insulin-induced hypoglycaemia in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160672     DOI: 10.1007/s00125-006-0519-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  33 in total

1.  Circulating insulin inhibits glucagon secretion induced by arginine in type 1 diabetes.

Authors:  P R Oskarsson; P E Lins; B Ahré; U C Adamson
Journal:  Eur J Endocrinol       Date:  2000-01       Impact factor: 6.664

2.  Effects of arterial versus venous sampling on analysis of glucose kinetics in man.

Authors:  E A McGuire; J H Helderman; J D Tobin; R Andres; M Berman
Journal:  J Appl Physiol       Date:  1976-10       Impact factor: 3.531

3.  Blood glucose area under the curve. Methodological aspects.

Authors:  J P Le Floch; P Escuyer; E Baudin; D Baudon; L Perlemuter
Journal:  Diabetes Care       Date:  1990-02       Impact factor: 19.112

4.  Control of gluconeogenesis in liver. IV. Differential effects of fatty acids and glucagon on ketogenesis and gluconeogenesis in the perfused rat liver.

Authors:  J H Exton; J G Corbin; C R Park
Journal:  J Biol Chem       Date:  1969-08-10       Impact factor: 5.157

Review 5.  Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Authors:  B E Dunning; J E Foley; B Ahrén
Journal:  Diabetologia       Date:  2005-08-13       Impact factor: 10.122

6.  The antiketogenic effect of alanine in normal man: evidence for an alanine-ketone body cycle.

Authors:  R Nosadini; K G Alberti; D G Johnston; S Del Prato; C Marescotti; E Duner
Journal:  Metabolism       Date:  1981-06       Impact factor: 8.694

7.  Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans.

Authors:  Francesca Porcellati; Simone Pampanelli; Paolo Rossetti; Cristina Cordoni; Stefania Marzotti; Luciano Scionti; Geremia B Bolli; Carmine G Fanelli
Journal:  Diabetes       Date:  2003-11       Impact factor: 9.461

8.  Glycemic actions of alanine and terbutaline in IDDM.

Authors:  B V Wiethop; P E Cryer
Journal:  Diabetes Care       Date:  1993-08       Impact factor: 19.112

9.  Effects of dipeptide administration on hypoglycaemic counterregulation in type 1 diabetes.

Authors:  J M'bemba; L Cynober; P de Bandt; M Taverna; A Chevalier; C Bardin; G Slama; J L Selam
Journal:  Diabetes Metab       Date:  2003-09       Impact factor: 6.041

10.  Evidence against important catecholamine compensation for absent glucagon counterregulation.

Authors:  P De Feo; G Perriello; E Torlone; C Fanelli; M M Ventura; F Santeusanio; P Brunetti; J E Gerich; G B Bolli
Journal:  Am J Physiol       Date:  1991-02
View more
  9 in total

1.  Cross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte.

Authors:  Kirk M Habegger
Journal:  Diabetes       Date:  2022-09-01       Impact factor: 9.337

Review 2.  Mini-review: Glucagon responses in type 1 diabetes - a matter of complexity.

Authors:  Mads Bisgaard Bengtsen; Niels Møller
Journal:  Physiol Rep       Date:  2021-08

3.  Hypoglycemia: from the laboratory to the clinic.

Authors:  Stephanie A Amiel
Journal:  Diabetes Care       Date:  2009-08       Impact factor: 17.152

4.  Hormonal modulation of hepatic cAMP prevents estradiol 17β-D-glucuronide-induced cholestasis in perfused rat liver.

Authors:  Andrés E Zucchetti; Ismael R Barosso; Andrea C Boaglio; Marcelo G Luquita; Marcelo G Roma; Fernando A Crocenzi; Enrique J Sánchez Pozzi
Journal:  Dig Dis Sci       Date:  2013-01-31       Impact factor: 3.199

Review 5.  Minimizing hypoglycemia while maintaining glycemic control in diabetes.

Authors:  Simon R Heller
Journal:  Diabetes       Date:  2008-12       Impact factor: 9.461

6.  Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people.

Authors:  Paolo Rossetti; Francesca Porcellati; Natalia Busciantella Ricci; Paola Candeloro; Patrizia Cioli; K Sreekumaran Nair; Fausto Santeusanio; Geremia B Bolli; Carmine G Fanelli
Journal:  Diabetes       Date:  2008-04-04       Impact factor: 9.461

7.  Parallel Multi-Omics in High-Risk Subjects for the Identification of Integrated Biomarker Signatures of Type 1 Diabetes.

Authors:  Oscar Alcazar; Luis F Hernandez; Ernesto S Nakayasu; Carrie D Nicora; Charles Ansong; Michael J Muehlbauer; James R Bain; Ciara J Myer; Sanjoy K Bhattacharya; Peter Buchwald; Midhat H Abdulreda
Journal:  Biomolecules       Date:  2021-03-04

8.  Prolonged Low-Dose Dioxin Exposure Impairs Metabolic Adaptability to High-Fat Diet Feeding in Female but Not Male Mice.

Authors:  Geronimo Matteo; Myriam P Hoyeck; Hannah L Blair; Julia Zebarth; Kayleigh R C Rick; Andrew Williams; Rémi Gagné; Julie K Buick; Carole L Yauk; Jennifer E Bruin
Journal:  Endocrinology       Date:  2021-06-01       Impact factor: 4.736

9.  Plasma Amino Acids Metabolomics' Important in Glucose Management in Type 2 Diabetes.

Authors:  Abdelrahim Alqudah; Mohammed Wedyan; Esam Qnais; Hassan Jawarneh; Lana McClements
Journal:  Front Pharmacol       Date:  2021-07-15       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.